Now on Sale Biosante up to 75 % of Retail Market Price. Hurry these prices won`t last!
The following will show you companies selling for far above BPAX with a fraction their pipeline diversity or proven ability to get FDA approval.
Sangamo Bioscience - has 1 Phase II and two Phase I/II clinical Market Cap = $222.48 mllion
Amicus Therapeutics - has 1 phase III and 1 phase II trials Market Cap = $232.18 million
Corcept Therapeutics - 1 awaiting PUDFA, one phase II trial Market Cap= $232.48 million
Cadence pharmaceuticals - has one approved drug and nothing in the pipeline that I can see. Market Cap= $256.37 million
Geron Corp. has 6 phase II trials. Market Cap =$262.29 million
Arena Pharmaceuticals has 1 product FDA issued CRL October 2010, 1 phase II Market Cap =$283.29 million
Navidea Biopharmaceuticals has one product just approved , and 2 phase III trials Market cap = $ 304.35 million
MannKind Corp. has 1 phase III trial Market Cap = $306.02 million
Chelsea therapeutics has 1 phase III trial and 4 phase II trials market cap = $308.62 million
Anthera pharmaceuticals has 1 phase III and 2 phase II trials Market Cap $318.26 million
Progenics Pharmaceuticals has 1 approved product, 1 FDA approval, 1 phase III trial and 1 phase II trial Market Cap = $321.08 million
Aegerion Pharmaceuticals – Has 1 phase III trial Market cap = $349.94 million
Oncotheryion has 1 phase III and 4 phase II trials Market Cap = $358.53 million
Ziopharm oncology 5 phase II trials Market Cap = $361.42 million
Oncolytics has 1 phase III trial and 9 phase II trials of Market Cap = $365.45 million (very similar to the BPAX cancer program)
Raptor Pharmaceuticals has 1 phase III and 3 phase II trials Market Cap = $372.16 million
Now look at Biosante
Biosante = Has 1 approved product , 1PUDFA decision this week, I in late stage phase 3 trials , 1 product in stage 2/3 trials, 3 phase 2 cancer trials awaiting money or partners to go to Phase 3 trials, Through the university a phase 2 trial being conducted in conjunction with the partner’s product. And 4 designated orphan drugs. In addition 16 % stake a company with 1 phase 2 cancer trial and a 19 % stake in another company with 2 phase 2 trials. Market Cap = $93.62 million
Now what do you think BPAX is worth?
